[go: up one dir, main page]

NI201000072A - Derivados 1, 2, 4 - triazol amino como moduladores de mglur5. - Google Patents

Derivados 1, 2, 4 - triazol amino como moduladores de mglur5.

Info

Publication number
NI201000072A
NI201000072A NI201000072A NI201000072A NI201000072A NI 201000072 A NI201000072 A NI 201000072A NI 201000072 A NI201000072 A NI 201000072A NI 201000072 A NI201000072 A NI 201000072A NI 201000072 A NI201000072 A NI 201000072A
Authority
NI
Nicaragua
Prior art keywords
modulators
compounds
mglur5
derivatives
amino
Prior art date
Application number
NI201000072A
Other languages
English (en)
Inventor
Isaac Methvin
Wallberg Andreas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201000072A publication Critical patent/NI201000072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con novedosos compuestos amino triazol 1,2,4 el método para su preparación, composiciones farmacéuticas conteniendo dichos compuestos y su uso en terapia. Los compuestos actuan como moduladores de receptores de glutamato metabotrópicos(mGluR) y son en consecuencia útiles en el tratamiento de las relaciones transitorias del esfinter esofágico inferior, la enfermedad de reflujo gastroesofágico, dolor, ansiedad y síndrome del intestino irritable.
NI201000072A 2007-10-26 2010-04-26 Derivados 1, 2, 4 - triazol amino como moduladores de mglur5. NI201000072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98295607P 2007-10-26 2007-10-26

Publications (1)

Publication Number Publication Date
NI201000072A true NI201000072A (es) 2011-03-24

Family

ID=40579779

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000072A NI201000072A (es) 2007-10-26 2010-04-26 Derivados 1, 2, 4 - triazol amino como moduladores de mglur5.

Country Status (21)

Country Link
US (1) US20090111821A1 (es)
EP (1) EP2212316A4 (es)
JP (1) JP2011500798A (es)
KR (1) KR20100089091A (es)
CN (1) CN101918399A (es)
AR (1) AR069030A1 (es)
AU (1) AU2008317544A1 (es)
BR (1) BRPI0818679A2 (es)
CA (1) CA2702974A1 (es)
CL (1) CL2008003182A1 (es)
CR (1) CR11391A (es)
DO (1) DOP2010000124A (es)
EA (1) EA201000656A1 (es)
IL (1) IL205289A0 (es)
MX (1) MX2010004362A (es)
NI (1) NI201000072A (es)
PE (1) PE20091348A1 (es)
TW (1) TW200922585A (es)
UY (1) UY31427A1 (es)
WO (1) WO2009054794A1 (es)
ZA (1) ZA201002854B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764339A1 (en) 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
WO2012076898A1 (en) 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
RU2495687C1 (ru) * 2012-06-19 2013-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Минздравсоцразвития Российской Федерации Способ лечения больных гастроэзофагеальной рефлюксной болезнью
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
EP2857387A1 (en) 2013-10-07 2015-04-08 Boehringer Ingelheim International Gmbh Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
US9745308B2 (en) 2014-09-12 2017-08-29 Chiesi Farmaceutici S.P.A. Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors
CA3075727A1 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420355D0 (en) * 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
EP0858803A4 (en) * 1995-08-28 2000-02-09 Showa Pharm Chem Ind COMPOSITION FOR LOCAL ANESTHESIA
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
EP1716125B1 (en) * 2004-02-18 2013-06-19 AstraZeneca AB Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
BRPI0507501A (pt) * 2004-02-18 2007-06-26 Astrazeneca Ab composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
WO2007111212A1 (ja) * 2006-03-24 2007-10-04 Eisai R & D Management Co., Ltd. トリアゾロン誘導体
TW200808777A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGLUR5 modulators III
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
TW200811156A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
TW200811137A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators II
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
EP2250165B1 (en) * 2007-12-21 2018-07-25 Merck Serono S.A. Triazole oxadiazoles derivatives
EP2276746A1 (en) * 2008-04-10 2011-01-26 Basf Se Substituted pyridazinylmethyl sulfonamides

Also Published As

Publication number Publication date
CN101918399A (zh) 2010-12-15
US20090111821A1 (en) 2009-04-30
EP2212316A1 (en) 2010-08-04
BRPI0818679A2 (pt) 2015-04-14
UY31427A1 (es) 2009-05-29
ZA201002854B (en) 2011-10-26
EP2212316A4 (en) 2012-06-27
AU2008317544A1 (en) 2009-04-30
WO2009054794A1 (en) 2009-04-30
JP2011500798A (ja) 2011-01-06
IL205289A0 (en) 2010-12-30
TW200922585A (en) 2009-06-01
CL2008003182A1 (es) 2009-11-27
KR20100089091A (ko) 2010-08-11
CR11391A (es) 2010-08-05
EA201000656A1 (ru) 2010-12-30
AR069030A1 (es) 2009-12-23
PE20091348A1 (es) 2009-10-04
DOP2010000124A (es) 2010-10-15
CA2702974A1 (en) 2009-04-30
MX2010004362A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
NI201000072A (es) Derivados 1, 2, 4 - triazol amino como moduladores de mglur5.
CO6561821A2 (es) Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms
SV2008001369A (es) Benzimidazoles
ECSP099370A (es) Derivados de hidantoína usados como inhibidores de mmp
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
CY1112232T1 (el) Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
CY1111603T1 (el) Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa
CL2008003811A1 (es) Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor.
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
UY28936A1 (es) Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq)
TW200610527A (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
HN2010000432A (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
PT1716152E (pt) Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
CY1118314T1 (el) Συνδυασμοι αγωνιστων υποδοχεα σεροτονινης για την αγωγη κινητικων διαταραχων
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii